The RCF includes an uncommitted increase option in an amount of EUR 40 million and is complemented by the extension of the existing CHF 40 million credit facility granted by Draupnir Holding B.V., PolyPeptide’s majority shareholder. The RCF will allow PolyPeptide to refinance its existing borrowings from banks as well as to finance its working capital and capital expenditure requirements to support its planned business growth. PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. The NKF team was led by M&A/Finance partner Philip Spoerlé, working with associate Selim Lötscher (M&A/Finance) and partner Markus Kronauer (Tax).

---